In a new @BiotechTV interview, CEO Bent Jakobsen expands on the unique value of our tumour-targeted viral delivery technology and discusses highlights from a strong year at Accession Therapeutics – including advancement of our lead programme into the clinic and today’s financing

We’re pleased to announce that Accession Therapeutics has completed a £30.5 million ($40 million USD) fundraise to advance the development of our TROCEPT platform. The investment will support the generation of full clinical data from our ongoing Phase 1 study of TROCEPT-01

Great to have our Head of Research David Cole represent us at #PEGSEurope last week. 🎙️In the Next-Gen Viral Immunotherapies track, Dave presented our TROCEPT platform – designed for IV, tumour-selective delivery – and shared an update on our lead clinical programme. 🧬 He also

🔬Our tumour-selective viral vector is engineered to bypass normal tissue, target αvβ6 integrin on carcinomas and express a potent checkpoint inhibitor within tumours. 👀See how our virus selectively replicates in cancer cells and releases immune payloads to turn cold tumours

🎬What’s behind the ATTEST trial? Accession Therapeutics CEO Bent Jakobsen and Lead Investigator Prof. Adel Samson @UniversityLeeds discuss the science driving our first-in-human study of TROCEPT-01. 🎥 Watch now https://t.co/h1S3rp1tco #Biotech #ImmunoOncology #CancerTrials

🎯Milestone reached: We are proud to announce that the first patient has been dosed in our Phase 1 ATTEST trial of TROCEPT-01 (ATTR-01), a tumour-activated viral immunotherapy for local checkpoint inhibitor expression after IV delivery. Targeted. Tuned. Tumour-selective. 🔗

🎙️Our Head of Research David Cole takes centre stage at #PEGS2025 🎯 Chair - Next-Generation Viral Immunotherapies: From Design to Delivery Speaker - Tumour-Activated Checkpoint Expression in Cancer Immunotherapy Join us in Lisbon from 11-13 November or explore the science

What an inspiring week at #SITC25. We were proud to share three posters, including preclinical data on TROCEPT and the Phase 1 TROCEPT-01 (ATTR-01) study in solid tumours. Thank you to all who attended our poster presentations and engaged with our team. 🔗Learn more:

We’re heading to #BIOEurope 2025 (Vienna) and #SITC2025 (National Harbor, MD) in November! Connect with us to discuss next-gen viral immunotherapy and our TROCEPT platform now entering the clinic. 🎥 WATCH to see how a focused team, robust science and clear purpose are

Thanks to all who connected with us at #ESMO25. Our poster on ATTR-01 — an αvβ6-targeted oncolytic adenovirus delivering anti-PD-L1 directly into tumours — is now available online. 🔗 View the poster  https://t.co/2vSxay7xKr #ImmunoOncology #OncolyticVirus #ClinicalTrials

#ESMO25 opens today. We’re sharing new details of the ATTEST study, the first-in-human trial of ATTR-01 (TROCEPT-01), an αvβ6-targeted oncolytic adenovirus that delivers anti-PD-L1 directly into tumours following IV administration. Learn more about the study and our approach to

Thrilled to present new clinical progress at #ESMO25 later this week: our Trial in Progress poster on ATTR-01 (TROCEPT-01), a novel oncolytic adenovirus targeting αvβ6 & locally expressing anti-PD-L1. Find us in the Poster Hall #3780. 👉 More on our pipeline:

Live now ➡️ Our CDO on the Bench to Bedside #Biomarkers panel at Biomarkers & Precision Medicine @OGPREMED. In ATTEST, our Phase 1 trial, biomarkers aren’t add-ons - they guide patient selection, shape readouts & provide evidence TROCEPT’s tumour-targeted activity. 👉 Follow our

Behind every platform is a team with the focus and discipline to deliver. Meet the people driving Accession Therapeutics forward. 🔗 https://t.co/6NAVTZFz3m #Biotech #ImmunoOncology #InvestorRelations

Systemic. Targeted. Potent. TROCEPT is designed to reprogramme tumours from within. Meet us this week at LSXBoston and BioCentury Grand Rounds Europe. #Biotech #ImmunoOncology

At #CICON2025 we’re sharing new data on TROCEPT, our tumour-targeted immunotherapy. •Tumour selectivity: Harnesses αvβ6 integrin to deliver >100x more virus to tumours than to the liver •Local immune activation: TROCEPT-01 (ATTR-01) expresses anti-PD-L1 inside tumours, not

Five TROCEPT abstracts accepted for presentation at #ESMO25, #SITC25, and #CICON25, spanning both clinical & preclinical research, including the Phase 1 clinical trial with TROCEPT-01 (ATTR-01) in patients with solid tumours (ATTEST). Details:

Now live: Targeting the Untreatable. TROCEPT is designed to make tumours visible to the immune system by producing immune-activating drugs directly inside the tumour Scroll down to watch the story under 'About Us': https://t.co/r1UzoESgr8 #Biotech #CancerResearch #TROCEPT